Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Information

v3.23.2
Balance Sheet Information
 6 Months Ended
Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Information Balance Sheet Information
Cash, Cash Equivalents and Restricted Cash
A summary of cash and cash equivalents and restricted cash is as follows:
June 30, 2023 December 31, 2022
Cash and Cash Equivalents $ 7,951,650  $ 5,964,556 
Restricted Cash, Non-current 4,150  49,260 
Total Cash, Cash Equivalents and Restricted Cash $ 7,955,800  $ 6,013,816 
Non-current restricted cash consists of deposits with financial institutions for corporate credit cards.
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
June 30, 2023 December 31, 2022
Prepaid Insurance $ 112,307  $ 117,315 
Prepaid Research and Development 86,352  128,429 
Other 67,841  97,325 
Total Prepaid Expenses and Other Current Assets $ 266,500  $ 343,069 
Accrued Expenses
Accrued expenses consist of the following:
June 30, 2023 December 31, 2022
Payroll and Benefits $ 1,051,087  $ 1,312,443 
Professional Fees 93,684  282,721 
Clinical Trials 209,653  57,020 
Other 44,610  183,750 
Total Accrued Expenses $ 1,399,034  $ 1,835,934